Modulation of brain-derived neurotrophic factor as a potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 8, 2009, Pages 1401-1408

  Bousquet, M ^a   Gibrat, C ^a   Saint Pierre, M ^a   Julien, C ^a   Calon, F ^a,b   Cicchetti, F ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Brain derived neurotrophic factor; DHA; MPTP; Parkinson's disease; TrkB

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MESSENGER RNA; OMEGA 3 FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DIET THERAPY; FAT INTAKE; GENE EXPRESSION; MALE; MOTOR CORTEX; MOUSE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FATTY ACIDS, OMEGA-3; GENE EXPRESSION REGULATION; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RECEPTOR, TRKB; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE;

EID: 71549124927     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.07.018     Document Type: Article

References (59)

1. Akbar M., Calderon F., Wen Z., and Kim H.Y. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci U S A 102 (2005) 10858-10863
2. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389 (1997) 856-860
3. Appleton K.M., Rogers P.J., and Ness A.R. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev 21 (2008) 13-41
4. Baquet Z.C., Bickford P.C., and Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 25 (2005) 6251-6259
5. Bazan N.G. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 15 (2005) 159-166
6. Benisty S., Boissiere F., Faucheux B., Agid Y., and Hirsch E.C. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study. Neuroscience 86 (1998) 813-826
7. Boudrault C., Bazinet R.P., and Ma D.W. Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. J Nutr Biochem 20 (2009) 1-10
8. Bousquet M., Saint-Pierre M., Julien C., Salem Jr. N., Cicchetti F., and Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. Faseb J 22 (2008) 1213-1225
9. Brown L.L., Feldman S.M., Smith D.M., Cavanaugh J.R., Ackermann R.F., and Graybiel A.M. Differential metabolic activity in the striosome and matrix compartments of the rat striatum during natural behaviors. J Neurosci 22 (2002) 305-314
10. Calder P.C. Polyunsaturated fatty acids and inflammation. Biochem Soc Trans 33 (2005) 423-427
11. Calon F., and Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 77 (2007) 287-293
12. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43 (2004) 633-645
13. Calon F., Lim G.P., Morihara T., Yang F., Ubeda O., Salem Jr. N., et al. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 22 (2005) 617-626
14. Curtis C.L., Hughes C.E., Flannery C.R., Little C.B., Harwood J.L., and Caterson B. n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem 275 (2000) 721-724
15. da Silva T.M., Munhoz R.P., Alvarez C., Naliwaiko K., Kiss A., Andreatini R., et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 111 (2008) 351-359
16. de Lau L.M., Bornebroek M., Witteman J.C., Hofman A., Koudstaal P.J., and Breteler M.M. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 64 (2005) 2040-2045
17. De Smedt-Peyrusse V., Sargueil F., Moranis A., Harizi H., Mongrand S., and Laye S. Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization. J Neurochem 105 (2008) 296-307
18. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 Pt 5 (1991) 2283-2301
19. Freund-Levi Y., Eriksdotter-Jonhagen M., Cederholm T., Basun H., Faxen-Irving G., Garlind A., et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63 (2006) 1402-1408
20. Galli C., Marangoni F., and Galella G. Modulation of lipid derived mediators by polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 48 (1993) 51-55
21. Gerfen C.R. The neostriatal mosaic: striatal patch-matrix organization is related to cortical lamination. Science 246 (1989) 385-388
22. Gibrat C., Saint-Pierre M., Bousquet M., Levesque D., Rouillard C., and Cicchetti F. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem 109 (2009) 1469-1482
23. Green K.N., Martinez-Coria H., Khashwji H., Hall E.B., Yurko-Mauro K.A., Ellis L., et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 27 (2007) 4385-4395
24. Green J.T., Orr S.K., and Bazinet R.P. The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. J Lipid Res 49 (2008) 939-944
25. Hashimoto M., Hossain S., Shimada T., Sugioka K., Yamasaki H., Fujii Y., et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 81 (2002) 1084-1091
26. Hibbeln J.R. Fish consumption and major depression. Lancet 351 (1998) 1213
27. Hofer M., Pagliusi S.R., Hohn A., Leibrock J., and Barde Y.A. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. Embo J 9 (1990) 2459-2464
28. Julien C., Berthiaume L., Hadj-Tahar A., Rajput A.H., Bedard P.J., Di Paolo T., et al. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int 48 (2006) 404-414
29. Jump D.B. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277 (2002) 8755-8758
30. Kastin A.J., Akerstrom V., and Pan W. Glial cell line-derived neurotrophic factor does not enter normal mouse brain. Neurosci Lett 340 (2003) 239-241
31. Kim H.Y. Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem 282 (2007) 18661-18665
32. Knott C., Stern G., Kingsbury A., Welcher A.A., and Wilkin G.P. Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra. Parkinsonism Relat Disord 8 (2002) 329-341
33. Knott C., Stern G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16 (2000) 724-739
34. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 339 (1998) 1044-1053
35. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. Faseb J 18 (2004) 717-719
36. Levant B., Ozias M.K., Davis P.F., Winter M., Russell K.L., Carlson S.E., et al. Decreased brain docosahexaenoic acid content produces neurobiological effects associated with depression: interactions with reproductive status in female rats. Psychoneuroendocrinology 33 (2008) 1279-1292
37. Lim S.Y., Fox S.H., and Lang A.E. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 66 (2009) 167-172
38. Logan A.C. Neurobehavioral aspects of omega-3 fatty acids: possible mechanisms and therapeutic value in major depression. Altern Med Rev 8 (2003) 410-425
39. Lucas M., Asselin G., Merette C., Poulin M.J., and Dodin S. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 89 (2009) 641-651
40. Marcheselli V.L., Hong S., Lukiw W.J., Tian X.H., Gronert K., Musto A., et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278 (2003) 43807-43817
41. Michael-Titus A.T. Omega-3 fatty acids and neurological injury. Prostaglandins Leukot Essent Fatty Acids 77 (2007) 295-300
42. Middlemas D.S., Lindberg R.A., and Hunter T. trkB, a neural receptor protein-tyrosine kinase: evidence for a full-length and two truncated receptors. Mol Cell Biol 11 (1991) 143-153
43. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 270 (1999) 45-48
44. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., Bennett D.A., Wilson R.S., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60 (2003) 940-946
45. Murer M.G., Yan Q., and Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63 (2001) 71-124
46. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. NeuroReport 10 (1999) 557-561
47. Paxinos G., and Franklin K.J. The mouse brain in stereotaxic coordinates (2001), Academic Press, San Diego 296
48. Peterson A.L., and Nutt J.G. Treatment of Parkinson's disease with trophic factors. Neurotherapeutics 5 (2008) 270-280
49. Rao J.S., Ertley R.N., Lee H.J., DeMar Jr. J.C., Arnold J.T., Rapoport S.I., et al. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 12 (2007) 36-46
50. Salem Jr. N., Litman B., Kim H.Y., and Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36 (2001) 945-959
51. Saucedo-Cardenas O., Quintana-Hau J.D., Le W.D., Smidt M.P., Cox J.J., De Mayo F., et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A 95 (1998) 4013-4018
52. Schaefer E.J., Bongard V., Beiser A.S., Lamon-Fava S., Robins S.J., Au R., et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63 (2006) 1545-1550
53. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21 (2002) 495-505
54. Soppet D., Escandon E., Maragos J., Middlemas D.S., Reid S.W., Blair J., et al. The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell 65 (1991) 895-903
55. Tremblay M.E., Saint-Pierre M., Bourhis E., Levesque D., Rouillard C., and Cicchetti F. Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging 27 (2006) 862-870
56. Venna V.R., Deplanque D., Allet C., Belarbi K., Hamdane M., and Bordet R. PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus. Psychoneuroendocrinology 34 (2009) 199-211
57. von Bohlen und Halbach O., Minichiello L., and Unsicker K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. Faseb J 19 (2005) 1740-1742
58. Wu A., Ying Z., and Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 21 (2004) 1457-1467
59. Wu A., Ying Z., and Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 155 (2008) 751-759